221 related articles for article (PubMed ID: 33309481)
1. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
4. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
6. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
File DM; Pascual T; Deal AM; Wheless A; Perou CM; Claire Dees E; Carey LA
Breast Cancer Res Treat; 2022 Nov; 196(1):153-162. PubMed ID: 36008651
[TBL] [Abstract][Full Text] [Related]
7. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
10. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
11. Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study.
Lao C; Kuper-Hommel M; Campbell I; Elwood M; Lawrenson R
N Z Med J; 2021 Nov; 134(1545):47-59. PubMed ID: 34788271
[TBL] [Abstract][Full Text] [Related]
12. The Difference in Prognostic Outcomes Between
Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
[TBL] [Abstract][Full Text] [Related]
13. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
14. Immediate Breast Reconstruction in De Novo Metastatic Breast Cancer: An Analysis of 563 Cases Based on the SEER Database.
Chen H; Zhang M; Wang M; Zhang P; Bai F; Wu K
Clin Breast Cancer; 2019 Feb; 19(1):e135-e141. PubMed ID: 30497928
[TBL] [Abstract][Full Text] [Related]
15. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
18. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
20. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
